Updates from the Third International Congress on Psoriasis: From Gene to Clinic, the Royal College of Physicians, London, U.K., 21-23 November 2002

British Journal of Dermatology

Volumn 148, Issue 5, 2003, Pages 878-884

  Camp, R D R ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; ALEFACEPT; ANTIBODY; CYCLOSPORIN; ETANERCEPT; HISTONE DEACETYLASE INHIBITOR; HLA C ANTIGEN; IC 747; INFLIXIMAB; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; METHOTREXATE; NATALIZUMAB; PIMECROLIMUS; TAZAROTENE; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 1;

ALLERGIC DISEASE; ANTIGEN EXPRESSION; AUTOIMMUNE DISEASE; BETA HEMOLYTIC STREPTOCOCCUS; CANCER RISK; CELL INFILTRATION; CHEILITIS; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CONFERENCE PAPER; CROHN DISEASE; DISEASE ACTIVITY; DRUG COST; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DYSESTHESIA; EROSION; ERYTHEMA; GENE; GENE IDENTIFICATION; GENE LOCUS; GENETIC CODE; GENETIC SUSCEPTIBILITY; HEADACHE; HEALTH CARE COST; HLA C GENE; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; IMMUNOTHERAPY; IMPAIRED GLUCOSE TOLERANCE; INFECTION; INFLAMMATION; INJECTION SITE; MEDICAL SOCIETY; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NEPHROTOXICITY; NONHUMAN; PATIENT MONITORING; PENETRANCE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; SINUSITIS; SKIN CANCER; SKIN MANIFESTATION; SOCIAL PSYCHOLOGY; TUBERCULOSIS; ULTRAVIOLET RADIATION; UNITED KINGDOM; UPPER RESPIRATORY TRACT INFECTION;

ANIMALS; ARTHRITIS, PSORIATIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; PSORIASIS; STREPTOCOCCAL INFECTIONS; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037526338     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2003.05431.x     Document Type: Conference Paper

References (24)

1. Kere J. PSORS1: towards gene identification. Br J Dermatol 2002; 147: 1052 (Abstr.).
2. Nair RP, Stuart P, Henseler T et al. Progress in identification of the PSORS1 gene. Br J Dermatol 2002; 147: 1052 (Abstr.).
3. Veal CD, Capon F, Allen MH et al. Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locus. Br J Dermatol 2002; 147: 1052 (Abstr.).
4. Asumalahti K, Ameen M, Evans JC et al. Analysis of PSORS1 single nucleotide polymorphisms in guttate psoriasis and palmo-plantar pustulosis. Br J Dermatol 2002; 147: 1053 (Abstr.).
5. Reich K, Mössner R, Böddeker IR et al. Promoter polymorphisms of the genes encoding tumour necrosis factor-α and interleukin-1β are associated with different subtypes of psoriasis characterized by early and late disease onset. Br J Dermatol 2002; 147: 1054 (Abstr.).
6. Young HS, Summers AM, Bhushan M et al. Vascular endothelial growth factor polymorphisms and psoriasis. Br J Dermatol 2002; 147: 1054 (Abstr.).
7. Middleton LT. The promise of pharmacogenetics. Br J Dermatol 2002; 147: 1064 (Abstr.).
8. Lewis JS, Ravindran JS, Korendowych E et al. Prevalence and characteristics of undiagnosed psoriatic arthropathy in psoriasis: a challenge for genetic studies. Br J Dermatol 2002; 147: 1052 (Abstr.).
9. Gudjonsson JE, Thorarinsson AM, Sigurgeirsson B et al. Streptococcal throat infections cause exacerbation of chronic plaque psoriasis: a prospective study. Br J Dermatol 2002; 147: 1056 (Abstr.).
10. Thorleifsdottir RH, Gudjonsson JE, Sigmundsdottir H et al. Skin-homing features of T lymphocytes in blood, tonsils and mesenteric lymph nodes. Br J Dermatol 2002; 147: 1061 (Abstr.).
11. Prinz JC, Vollner S. The clonally selected T cells of psoriatic skin lesions can be detected in the fraction of CLA-positive tonsillar T cells of psoriasis patients with streptococcal sore throat. Br J Dermatol 2002; 147: 1061 (Abstr.).
12. Luger T. Neuropeptides and skin inflammation. Br J Dermatol 2002; 147: 1055 (Abstr.).
13. Pincelli C, Marconi A, Giannetti A. Nerve growth factor and its receptors in keratinocytes: a role in the pathogenesis of psoriasis? Br J Dermatol 2002; 147: 1055-6 (Abstr.).
14. Nestle FO. Chemokines and their receptors in psoriasis. Br J Dermatol 2002; 147: 1060 (Abstr.).
15. Boyman O, Hefti HP, Suter M et al. TNF-alpha-dependent induction of psoriasis in the absence of lymphocyte recruitment. Br J Dermatol 2002; 147: 1059 (Abstr.).
16. Yu H, Mrowietz U. Expression of TGFβ and TGFβ-signalling SMAD proteins in psoriasis skin. Br J Dermatol 2002; 147: 1068 (Abstr.).
17. Richards HL, Mason DL, Kirby B et al. Hypocortisolic response to social stress in psoriasis patients. Br J Dermatol 2002; 147: 1057 (Abstr.).
18. Feldmann M, Brennan FM, Paleolog E et al. Anti-TNF therapy in rheumatoid arthritis: a useful tool for learning about pathogenesis of chronic inflammatory disease. Br J Dermatol 2002; 147: 1055 (Abstr.).
19. Chaudhari U, Romano P, Mulcahy LD et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-7.
20. Lowe NJ, Yamauchi P, Risk D et al. Etanercept as monotherapy in patients with psoriasis: clinical and pathological improvements following treatment. Br J Dermatol 2002; 147: 1064-5 (Abstr.).
21. Heydendael VMR, Spuls PI, Opmeer BC et al. Effectiveness, safety and quality of life of methotrexate versus cyclosporine A in moderate to severe psoriasis: a randomized controlled trial. Br J Dermatol 2002; 147: 1058 (Abstr.).
22. Ritchie JWA, La Thangue NB, Romero MR et al. PXD101, a novel inhibitor of histone deacetylase, is a potent inhibitor of keratinocyte proliferation and production of inflammatory mediators in vitro. Br J Dermatol 2002; 147: 1058-9 (Abstr.).
23. Walker PS, Menter MA, Weinstein GD et al. Oral tazarotene for the treatment of moderate to severe plaque psoriasis. Br J Dermatol 2002; 147: 1061-2 (Abstr.).
24. Gerber W, Ha AT, Hermann J, Ockenfels HM. Efficacy of a new anti-psoriatic phototherapy using a 308-nm excimer laser: results of a prospective study. Br J Dermatol 2002; 147: 1063 (Abstr.).